Behavioral Neurocardiac Training and Hypertension
- Conditions
- Hypertension
- Interventions
- Behavioral: Behavioral neurocardiac trainingBehavioral: Autogenic relaxation training
- Registration Number
- NCT00811811
- Lead Sponsor
- University Health Network, Toronto
- Brief Summary
This randomized controlled trial will examine whether behavioral neurocardiac training with heart rate variability biofeedback (BNT) augments reduction in ambulatory daytime and 24-hour SBP, DBP and PP, in comparison to an active control intervention (AC, autogenic relaxation training), among subjects diagnosed with hypertension, and following adjustment for medications. In addition, the independent association between the BNT and AC interventions on vagal-heart rate modulation and baroreflex sensitivity will be evaluated during a standardized assessment protocol of mental stress testing. This study extends a previous trial conducted at the UHN, in which we reported that the biofeedback intervention independently augments vagal-heart rate modulation, while reducing symptoms of stress and depressed mood, among subjects diagnosed with cardiovascular disease. Exploratory features of this trial will examine the association between ambulatory blood pressure, vagal-heart rate modulation, baroreflex sensitivity, and markers of inflammatory activity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 65
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Behavioral neurocardiac training Behavioral neurocardiac training 2 Autogenic relaxation training Autogenic relaxation training
- Primary Outcome Measures
Name Time Method Ambulatory daytime and 24-hour systolic blood pressure, diastolic blood pressure, and pulse pressure. Baseline and Post-treatment (following 6 treatment sessions scheduled over an 8-week interval)
- Secondary Outcome Measures
Name Time Method RR interval, vagal-heart rate modulation (high frequency power in RR interval variability [0.15-0.40 Hz/ms2]) and baroreflex sensitivity 8 weeks
Trial Locations
- Locations (1)
Toronto General Hospital
🇨🇦Toronto, Ontario, Canada